Medicenna recognizes that patient participation in clinical trials is critical in order to advance treatment for cancer and is developing its lead product, MDNA55, for cancers that have a significant unmet medical need.

MDNA55 is currently being studied in clinical trials for treatment of CNS cancers.

Phase 2 Clinical Trial Open To Enrollment

In December of 2016, Medicenna announced the initiation of its Phase 2 trial of MDNA55 in adults with recurrent Glioblastoma where MDNA55 is administered intratumorally using one infusion.

Hospitals Participating in this clinical trial include:

United States:

  • California
    • University of California San Francisco – San Francisco, California, United States, 94143 Recruiting
    • John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, California, United States, 90404 Recruiting
  • Florida
    • Marcus Neuroscience Institute at Boca Raton Regional Hospital, Boca Raton, Florida, United States, 33486 Recruiting
  • North Carolina
    • Duke University Medical Center, Durham, North Carolina, United States, 27710 Recruiting
      • Contact: Brain Tumor Center - Phone: 919-684-5301
      • Principal Investigator: Dina Randazzo, MD
  • Ohio
    • Cleveland Clinic, Cleveland, Ohio, United States, 44195 Recruiting
  • Oregon
    • Oregon Health and Science University, Portland, Oregon, United States, 97239 Recruiting
  • Pennsylvania
    • Hospital of the University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States, 19104 Recruiting
  • Texas
    • Cancer Therapy and Research Center At The University of Texas Health Science Center At San Antonio, San Antonio, Texas, United States, 78229 Recruiting

For more information about this study, including study design, eligibility criteria and up to date contact information for the participating hospitals please visit trial record (NCT02858895) on

Find Open Clinical Trials

Search to find out if other clinical trials exist for a specific medicine for a particular disease.